The following review on “Objective Assessment of Cancer Genes for Drug Discovery” has been published by Mishal N. Patel et.al., in Nature Reviews Drug Discover
Selecting the best targets is a key challenge for drug discovery, and achieving this effectively, efficiently and systematically is particularly important for prioritizing candidates from the sizeable lists of potential therapeutic targets that are now emerging from large-scale multi-omics initiatives, such as those in oncology.
Mishal Patel et al., described an objective, systematic, multifaceted computational assessment of biological and chemical space that can be applied to any human gene set to prioritize targets for therapeutic exploration.
This approach has been used to evaluate an exemplar set of 479 cancer-associated genes, reveal the tension between biological relevance and chemical tractability, and describe major gaps in available knowledge that could be addressed to aid objective decision-making.
The drug repurposing opportunities and identification of potentially druggable cancer-associated proteins that have been poorly explored with regard to the discovery of small-molecule modulators, despite their biological relevance were also proposed.
This abstract was published in Nature Reviews Drug Discover